Status
Please wait ...
EndoNet
The information resource about the endocrine network in human.
Search
Search a component
Browse
Browse pathways
Browse hormones
Browse hormones functions
Browse hormone classification
Browse receptors
Network
Load network
Path analysis
Process network
Help
Help
Statistic
About
Details for phenotype: Ovarian cancer
Top
General information
Triggers
Toolbox
Click to access the toolbox
Top
General information
Triggers
Toolbox
Click to access the toolbox
EndoNet ID: ENP00330
Add to network
Name
Ovarian cancer
General information
This phenotype is pathologic
Links to other resources
GO
positive regulation of organ growth
Medline Plus
000889
MeSH term
D010051
Disease database
9418
Phenotype triggers
more activity (high ligand concentration, overexpression) of
Lysophosphatidic acid receptor 2
ui-button
in
ovary
ui-button
LPA receptor 2 is a distinctive marker of ovarian cancer cells that transduces growth-promoting signals from the high local concentrations of LPA characteristic of aggressive ovarian cancer.
[1]
more activity (high ligand concentration, overexpression) of
Lysophosphatidic acid receptor 1
ui-button
in
ovary
ui-button
In addition to the involvement of LPA2, there is evidence for contribution of LPA1 to the tumorigenic activity of LPA. Genetic and pharmacological inhibition of LPA1 has been shown to reduce the proliferation and metastasis of OCCs.
[2]
more activity (high ligand concentration, overexpression) of
Lysophosphatidic acid receptor 3
ui-button
in
ovary
ui-button
LPAR3 may play a role in the development of ovarian cancer.
[3]
more activity (high ligand concentration, overexpression) of
Lysophosphatidic acid receptor 3
ui-button
in
ovary
ui-button
LPA3, in addition to LPA2, was associated with increased OCC aggressiveness in vivo due to their contribution to the tumorigenic activity of LPA.
[3]
more activity (high ligand concentration, overexpression) of
Lysophosphatidic acid receptor 2
ui-button
in
ovary
ui-button
LPA was shown to have potent protumorigenic effects on OCCs including cell survival, proliferation, increased migration and tissue invasion, activation of vascular endothelial growth factor, metalloproteinase, and urokinase-type plasminogen activator, and protection from cisplatin toxicity. These effects are mediated primarily by the activation of LPA2, which is known to promote proliferation, migration, and invasion of gynecological cancer cells in vitro and in vivo.
[4]
LPA2 is upregulated in OCCs and can be activated by low nanomolar concentrations of LPA, well below the basal serum concentration.
[5]
Reference
